CPA
DSGN icon

Capital Performance Advisors’s Design Therapeutics DSGN Stock Holding History

Capital Performance Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-143
Closed -$769 – 867
2024
Q3 		$769 Buy
+143
New +$673 ﹤0.01% 2046

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital Performance Advisors's DSGN Position: Q4 2024 in Review

Capital Performance Advisors sold out of Design Therapeutics (DSGN) in Q4 2024, closing a stake of 143 shares — an estimated $769 sold.

Capital Performance Advisors first reported a position in DSGN in Q3 2024 and held it in 1 quarter. The position peaked at $769 in Q3 2024. 95 funds tracked by Wall St. Rank hold DSGN as of Q4 2024.

  • Capital Performance Advisors reported no remaining Design Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 143 Design Therapeutics shares in Q4 2024, an estimated $769.
  • Capital Performance Advisors first reported a position in Design Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Design Therapeutics position peaked at $769 in Q3 2024.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.